Maze Therapeutics, Inc.

Christopher Joseph Sinz

David John Morgans, Jr

Patrick Sang Tae Lee

Birong Zhang

Alexander Wayne Schammel

Adam Neil Reid

Sarah M Bronner

Maarten Hoek

Chris Ziebenhaus

Todd Jonathan August Ewing

Victoria Anne Assimon

Walter Won

Kevin T Mellem

Hannah L Powers

Provided herein are compounds of formula (II):

APOL1 inhibitors and methods of use

Provided herein are compounds of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, R, R, R, L, L, L, R, X, X, X, and Xare as defined herein. Also provided are methods of preparing compounds of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1-mediated disease, disorder, or condition in an individual.

Provided herein are compounds of formula (I'): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y, Y, L, L, X, X, X, X, X, Q, R, R, R, R, and Rare as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (I&#x2032;). Also provided herein are methods of inhibiting GYS1 and methods of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.

Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof

Growing community of inventors

Walnut Creek, CA, United States of America

Christopher Joseph Sinz